Study of IMC-11F8 in Participants With Colorectal Cancer

NCT00835185 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

BIOLOGICAL: IMC-11F8 (necitumumab)
DRUG: Oxaliplatin
DRUG: Folinic acid (FA)
DRUG: 5-FU

Sponsor

Eli Lilly and Company